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Summary
Background Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of 
care in hormone-sensitive prostate cancer have emerged. In order to investigate the eﬀ ects of these therapies and to 
respond to emerging evidence, we aimed to systematically review all relevant trials using a framework for adaptive 
meta-analysis. 
Methods For this systematic review and meta-analysis, we searched MEDLINE, Embase, LILACS, and the Cochrane 
Central Register of Controlled Trials, trial registers, conference proceedings, review articles, and reference lists of trial 
publications for all relevant randomised controlled trials (published, unpublished, and ongoing) comparing either 
standard of care with or without docetaxel or standard of care with or without bisphosphonates for men with high-risk 
localised or metastatic hormone-sensitive prostate cancer. For each trial, we extracted hazard ratios (HRs) of the eﬀ ects 
of docetaxel or bisphosphonates on survival (time from randomisation until death from any cause) and failure-free 
survival (time from randomisation to biochemical or clinical failure or death from any cause) from published trial 
reports or presentations or obtained them directly from trial investigators. HRs were combined using the ﬁ xed-eﬀ ect 
model (Mantel-Haenzsel). 
Findings We identiﬁ ed ﬁ ve eligible randomised controlled trials of docetaxel in men with metastatic (M1) disease. 
Results from three (CHAARTED, GETUG-15, STAMPEDE) of these trials (2992 [93%] of 3206 men randomised) 
showed that the addition of docetaxel to standard of care improved survival. The HR of 0·77 (95% CI 0·68–0·87; 
p<0·0001) translates to an absolute improvement in 4-year survival of 9% (95% CI 5–14). Docetaxel in addition to 
standard of care also improved failure-free survival, with the HR of 0·64 (0·58–0·70; p<0·0001) translating into a 
reduction in absolute 4-year failure rates of 16% (95% CI 12–19). We identiﬁ ed 11 trials of docetaxel for men with 
locally advanced disease (M0). Survival results from three (GETUG-12, RTOG 0521, STAMPEDE) of these trials 
(2121 [53%] of 3978 men) showed no evidence of a beneﬁ t from the addition of docetaxel (HR 0·87 [95% CI 
0·69–1·09]; p=0·218), whereas failure-free survival data from four (GETUG-12, RTOG 0521, STAMPEDE, 
TAX 3501) of these trials (2348 [59%] of 3978 men) showed that docetaxel improved failure-free survival 
(0·70 [0·61–0·81]; p<0·0001), which translates into a reduced absolute 4-year failure rate of 8% (5–10). We identiﬁ ed 
seven eligible randomised controlled trials of bisphosphonates for men with M1 disease. Survival results from 
three of these trials (2740 [88%] of 3109 men) showed that addition of bisphosphonates improved survival (0·88 
[0·79–0·98]; p=0·025), which translates to 5% (1–8) absolute improvement, but this result was inﬂ uenced by the 
positive result of one trial of sodium clodronate, and we found no evidence of a beneﬁ t from the addition of 
zoledronic acid (0·94 [0·83–1·07]; p=0·323), which translates to an absolute improvement in survival of 2% (–3 to 
7). Of 17 trials of bisphosphonates for men with M0 disease, survival results from four trials (4079 [66%] of 
6220 men) showed no evidence of beneﬁ t from the addition of bisphosphonates (1·03 [0·89–1·18]; p=0·724) or 
zoledronic acid (0·98 [0·82–1·16]; p=0·782). Failure-free survival deﬁ nitions were too inconsistent for formal 
meta-analyses for the bisphosphonate trials.
Interpretation The addition of docetaxel to standard of care should be considered standard care for men with M1 
hormone-sensitive prostate cancer who are starting treatment for the ﬁ rst time. More evidence on the eﬀ ects of 
docetaxel on survival is needed in the M0 disease setting. No evidence exists to suggest that zoledronic acid improves 
survival in men with M1 or M0 disease, and any potential beneﬁ t is probably small.
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Introduction
Prostate cancer is a major health problem worldwide 
and is the second most common cancer in men. With 
1∙1 million diagnoses (15% of all cancers diagnosed in 
men) and 307 000 deaths estimated to have taken 
place in 2012, prostate cancer has become the 
ﬁ fth leading cause of death from cancer in men 
worldwide.1
For many decades, initial (ﬁ rst-line) treatments for 
both locally advanced and metastatic prostate cancer 
have been surgical castration by bilateral orchidectomy 
or androgen deprivation therapy with luteinising 
hormone-releasing hormone agonists or antagonists.2 
The aim of these approaches is to reduce testosterone 
concentrations. However, the disease progresses in 
virtually all patients who have metastatic disease and in 
many patients with non-metastatic disease.3,4 A number 
of treatments, such as bisphosphonates, cytotoxic 
chemotherapy, new hormone therapies, and radium-223, 
have therefore been assessed in combination with 
primary androgen deprivation therapy with the aim of 
reducing progression rates and improving survival.
One such treatment, docetaxel (given with or without 
estramustine), was shown in two pivotal randomised 
controlled trials5,6 to improve survival in men with 
castrate-resistant prostate cancer that was no longer 
responsive to testosterone suppression alone. This 
ﬁ nding led to the international approval by regulatory 
authorities of docetaxel for this disease setting and a 
number of randomised controlled trials, in which men 
with metastatic or high-risk localised prostate cancer, 
starting long-term androgen deprivation therapy for the 
ﬁ rst time, were randomly assigned to receive standard 
androgen deprivation therapy-based treatment alone or 
supplemented with docetaxel (with or without other 
agents). Results from some of the largest of these 
trials have now emerged. In the CHAARTED7 and 
STAMPEDE8 trials, men with metastatic disease had 
signiﬁ cant improvements in survival with the addition 
of docetaxel, whereas results of the similar GETUG-15 
trial9,10 showed no evidence of a survival beneﬁ t from 
docetaxel. A small number of trials of docetaxel for men 
with non-metastatic disease have produced promising 
results for relapse or failure-free survival, but the eﬀ ect 
on survival is unclear.
Bisphosphonates are a class of drugs that have been 
shown to have a number of anti-cancer eﬀ ects.11 
In randomised controlled trials, the ﬁ rst-generation 
bisphosphonate, clodronate, delayed time to progression 
in men with bone metastases when given alongside 
long-term androgen deprivation therapy. Some evidence 
suggests that biphosphonates might improve survival.12 
Newer (third-generation) bisphosphonates, notably 
zoledronic acid, have been found to reduce the risk of 
skeletal complications (eg, fractures) in patients with 
bone metastases from breast cancer and castrate-resistant 
prostate cancer.13 In the wake of these results, a number 
of randomised controlled trials have been designed to 
investigate whether men who are commencing long-term 
androgen deprivation therapy for either metastatic or 
localised hormone-sensitive prostate cancer beneﬁ t from 
bisphosphonates.
As part of the wider Systemic Treatment Options for 
Prostate Cancer (STOpCaP) meta-analysis project, we 
aimed to systematically review all relevant randomised 
controlled trials that tested the addition of docetaxel or 
bisphosphonates to standard of care. We prospectively 
planned meta-analyses that would respond and adapt to 
the emergence of new trial results, while also assessing 
the potential eﬀ ect of trials that are yet to be completed 
or reported.
Methods
Systematic review and framework for adaptive 
meta-analysis
Standard systematic reviews of both aggregate and 
individual participant data can take many years to 
complete and are usually retrospective, so they cannot 
always keep pace with therapeutic developments. We 
therefore used a framework for adaptive meta-analysis 
(FAME) being developed by the MRC Clinical Trials 
Unit at UCL (London, UK) to rapidly and robustly assess 
the eﬀ ects of therapies and to respond to emerging 
evidence. The key principle is to systematically identify 
all trials using established methods, then synthesise 
what is already known about the eﬀ ects of therapies 
from aggregate data, and consider how trials that are 
ongoing or yet to be reported might aﬀ ect these results. 
Thus, we deliberately began the review process before 
many trials of docetaxel and bisphosphonates had been 
completed and reported so as to build a picture of how 
information and evidence of the eﬀ ects of these drugs 
might accumulate. This review process allowed us to 
decide prospectively when we were likely to have 
suﬃ  cient results or power, or both, for reliable aggregate 
data meta-analyses and to interpret our results, taking 
into account the possible eﬀ ect of any as yet unavailable 
evidence. This also helped us determine the potential 
value of updating meta-analyses, and whether these 
meta-analyses should be based on aggregate data or 
individual patient data.
Study selection and data extraction
Randomised controlled trials comparing either standard 
of care versus standard of care plus docetaxel or standard 
of care versus standard of care plus bisphosphonate (at a 
therapeutic dose) were eligible if they aimed to include 
men with high-risk localised or metastatic, hormone-
sensitive (ie, not castrate-resistant) prostate cancer. We 
had no formal exclusion criteria.
We sought to identify all trials, irrespective of whether 
a trial was ongoing or completed, published or 
unpublished, with no language restrictions. We 
searched MEDLINE,14 Embase,15 LILACS,16 and the 
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Cochrane Central Register of Controlled Trials from 
inception to Sept 30, 2015, using ﬁ lters to include only 
randomised controlled trials. These searches were 
supplemented by searching trial registers, conference 
proceedings, review articles, and reference lists of trial 
publications (appendix pp 1–5). Collaborators were 
asked throughout the project if they knew of any 
additional trials. CLV, LHMR, and SB assessed all 
relevant trial reports or protocols. Search terms used are 
listed in the appendix.
For all eligible trials, we extracted data on: the accrual 
period, actual or (if ongoing) planned number of 
participants; whether previous androgen deprivation 
therapy was allowed; control group treatments (eg, type 
of androgen deprivation therapy used); docetaxel dose 
and scheduling; bisphosphonate type; dose and duration 
of bisphosphonate treatment; median patient age; 
metastatic status; performance status; TNM status; 
Gleason score; and median PSA concentration at the 
start of androgen deprivation therapy. We also extracted 
reported survival and failure-free survival results by trial 
and by participant subgroup (if available) from 
published reports and presentations. If insuﬃ  cient data 
were available from published reports, we sought it 
directly from study investigators. We also extracted data 
on methods of sequence generation, allocation 
concealment,  completeness of outcome data reporting, 
and attrition from trial reports or protocols, or both, to 
assess the risk of bias of individual trials.17
Methods were prespeciﬁ ed and are available in an 
online protocol.
Outcomes
The primary outcome, survival, was deﬁ ned as the time 
from randomisation until death from any cause. The 
secondary outcome was failure-free survival. Although 
there is no widely accepted deﬁ nition of failure-free 
survival, for the purpose of this systematic review and 
meta-analysis, we deﬁ ned it as the time from 
randomisation to biochemical failure, clinical failure 
(local relapse or metastases), or death from any cause.
Statistical analysis
From our review of the completed and ongoing trials, we 
anticipated that results from the three largest trials of 
docetaxel in M1 disease, which included around 90% of 
For the protocol see http://www.
crd.york.ac.uk/PROSPERO/
display_record.
asp?ID=CRD42015020059
Figure 1: Study ﬂ ow chart
CRPC=castrate-resistant prostate cancer. *One trial (STAMPEDE)8 is eligible to be included in both docetaxel and bisphosphonate comparisons.  
4372 records retrieved from electronic 
 databases searching
 1213 from MEDLINE
 2355 from Embase
  617 from Cochrane Central
  187 from LILACS
769 records retrieved from 
 ClinicalTrials.gov and screened
3181 unique records screened 3 potentially eligible trials identiﬁed 
 via conference proceedings
49 assessed for eligibility
21 eligible trials
34 assessed for eligibility
1191 duplicates removed
35 included in systematic review
22 included in meta-analysis of bisphosphonate comparison*
   
14 included in docetaxel comparison*
738 irrelevant comparison
3132 irrelevant comparison
14 eligible trials
28 excluded
 14 duplicate references to the same trial
 14 ineligible after full paper screened
   12 not treatment dose
   1 CRPC
   1 not randomised controlled trial
20 excluded
 10 duplicate trials already identiﬁed via electronic 
       databases
 10 ineligible
  6 not treatment dose
  1 CRPC
  1 not randomised controlled trial
  2 irrelevant comparison
See Online for appendix
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Accrual period Number 
of 
patients
Control Treatment Metastatic 
status
Median 
age 
(range)
Gleason 
score of 
8–10 (%)
Performance 
status of 0–1 
(%)
Median 
follow-up 
(survival)
Treatment on 
progression (control 
group only)
Docetaxel trials
GETUG-1225,26 November, 
2002–
December, 2006
413 ADT (goserelin 10·8 mg 
every 3 months for 
3 years)
ADT plus docetaxel 
(70 mg/m² for four 
cycles) plus 
estramustine
M0 63
(46–77)
42% Unknown 7 years, 
6 months
Not reported
TAX 350127 December, 2005–
September, 2007
228 ADT (leuprolide 22·5 mg 
every 3 months for 
18 months)
ADT plus docetaxel 
(75 mg/m² every 
3 weeks for six cycles)
M0 61·9* 52% Unknown 3 years, 
3 months
Not reported
RTOG 052128 December, 
2005–August, 
2009
612 ADT (LHRH agonist plus 
oral anti-androgen plus 
RT)
ADT plus docetaxel 
(75 mg/m² every 
3 weeks for six cycles) 
plus prednisone
M0 66 
(unknown) 
84% Unknown 6 years Not reported
STAMPEDE 
(standard of 
care with or 
without 
docetaxel)8
September, 
2005–March, 
2013
1776 ADT (plus radiotherapy 
for M0 patients)
ADT plus docetaxel 
(75 mg/m² every 
3 weeks for six cycles) 
plus predisone
M0 and M1 65
(40–82)
70% 99% 3 years, 
6 months
40% received 
docetaxel (49% 
received life-extending 
treatments)
STAMPEDE 
(standard of 
care plus 
zoledronic 
acid with or 
without 
docetaxel)8
September, 
2005–March, 
2013
1186 ADT (plus radiotherapy 
for M0 patients) plus 
zoledronic acid (4 mg 
every 3–4 weeks for 
2 years)
ADT (plus 
radiotherapy for M0 
patients) + zoledronic 
acid (4 mg for 
3–4 weeks for 
2 years) plus 
docetaxel (75 mg/m2 
every 3 weeks for 
six cycles)
M0 and M1 66
(42–84)
71% 99% 3 years, 
6 months
36% received 
docetaxel (45% 
received life-extending 
treatments)
GETUG-159,10 October, 
2004–December, 
2008
385 ADT (LHRH agonist or 
surgical castration or 
combined androgen 
blockade)
ADT plus docetaxel 
(75 mg/m² every 3 
weeks for up to 
nine cycles)
M1 63·5
(57–70)
56% 100% 6 years, 
11 months
62% received 
docetaxel
CHAARTED7 July, 2006–
November, 2012
790 ADT (LHRH agonist or 
LHRH antagonist) or 
surgical castration
ADT plus docetaxel 
(75 mg/m² every 
3 weeks for six cycles)
M1 64
(36–91)
61% 98% 2 years, 
5 months
147 (51%) of 
287 men received 
docetaxel (104 of 
287 men received 
abiratarone or 
enzalutamide)
Bisphosphonate trials
PRO412 June, 
1994–December, 
1997
508 Local standard practice 
(radiotherapy or 
hormone therapy or 
both) plus placebo
Local standard 
practice plus 
clodronate (520 mg 
four times daily)
M0 69·5
(49–87)
Unknown 97% 12 years Not reported
RADAR21 October, 
2003–August, 
2007
1071 ADT (leuprorelin 22·5 mg 
for either 6 months or 
18 months)
ADT plus zoledronic 
acid (4 mg every 
3 months for 
18 months)
M0 68·8
(62·6–
73·3)
35% 100% 7 years, 
5 months
Secondary therapeutic 
intervention was 
needed in 78 men in 
the short-term 
androgen suppression 
group, and 61 men in 
the intermediate-
term androgen 
suppression group; 
nature of treatment 
not reported
ZEUS29 June, 
2004–August, 
2007
1433 ADT ADT plus zoledronic 
acid (4 mg every 
3 months for up to 
4 years)
M0 67
(44–87)
62% 100% 4 years, 
9 months
Not reported
STAMPEDE 
(standard of 
care with or 
without 
zoledronic 
acid)8
September, 
2005–March, 
2013
1777 ADT (plus radiotherapy 
for M0 patients)
ADT (plus 
radiotherapy for M0 
patients) plus 
zoledronic acid (4 mg 
every 3–4 weeks for 
2 years)
M0 and M1 66
(41–82)
69% 99% 3 years, 
7 months
40% received 
docetaxel (49% 
received life-extending 
treatments)
(Table 1 continues on next page)
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all potential participants, would become available by 
June, 2015, with a median follow-up of about 3–4 years. 
The typical 4-year survival reported in trials in this group 
of men was 40%, which we set as our baseline for 
predicting the power a meta-analysis of these trials would 
be likely to provide. We estimated that we would have 
about 70% power to detect an absolute diﬀ erence of 5% in 
4-year survival (hazard ratio [HR] 0·87) and more than 
99% power to detect a 10% diﬀ erence in 4-year survival 
(HR 0·75); these are the sort of moderate eﬀ ects one 
might expect in advanced prostate cancer. For the 
bisphosphonate comparison in M1 disease, we predicted 
that we would have results from trials that included about 
85% of all potential participants and, using the same 
baseline survival, would achieve about 65% power to 
detect an absolute diﬀ erence of 5% in 4-year survival and 
more than 99% power to detect a 10% diﬀ erence in 4-year 
survival. These estimates gave us a clear trigger to conduct 
meta-analyses in the M1 disease setting.
We were aware that mature results of trials in M0 
disease would lag behind those in the M1 setting owing 
to a more favourable prognosis, so we expected fewer 
data for the docetaxel and bisphosphonate comparisons 
(around 60% of potential participants). Nevertheless, 
on the basis of an average baseline 4-year survival of 
around 80% in the reported trials, we predicted that we 
would still have reasonable power (60%) to detect a 5% 
diﬀ erence in 4-year survival and more than 99% power 
to detect a 10% diﬀ erence in 4-year survival, allowing 
us to compare the evidence between the two settings 
and ascertain if and when further meta-analyses are 
needed.
For each trial, we extracted HRs of the eﬀ ects of 
docetaxel or bisphosphonates on survival and failure-free 
survival from trial reports, estimated them from published 
Kaplan-Meier curves or other summary statistics,18–20 or 
obtained them directly from trialists. For those multiarm 
trials8,21 for which HRs were not available for the 
comparison of interest, we obtained these data indirectly 
from other HRs. For example, we could obtain the HR for 
the addition of docetaxel to standard of care plus 
zoledronic acid versus standard of care plus zoledronic 
acid alone for the STAMPEDE trial8 from the ratio of the 
HRs for the separate comparisons of standard of care with 
or without zoledronic acid and standard of care with or 
without zoledronic acid plus docetaxel. 
We combined the HRs from each of the individual, 
eligible trials in a meta-analysis using the ﬁ xed-eﬀ ect 
model (Mantel-Haenzsel). We also used the random-
eﬀ ects model to assess the robustness of the results to 
the choice of this model for the primary analysis.22 
We assessed the heterogeneity in treatment eﬀ ects 
between trials using the I² statistic and χ² test. We 
planned to combine all trials and, providing that 
suﬃ  cient trials or data were available, preplanned 
analyses that would compare trials (or patients within 
trials) grouped by metastatic status, use of previous 
local treatment for prostate cancer, planned 
radiotherapy as part of the standard of care, type of 
and length of time on androgen deprivation therapy 
allowed before randomisation, total planned dose of 
docetaxel, additional agents in the docetaxel group 
only, type of bisphosphonate, and dose of zoledronic 
acid. We aimed to calculate a meta-analysis HR for 
Accrual period Number 
of 
patients
Control Treatment Metastatic 
status
Median 
age 
(range)
Gleason 
score of 
8–10 (%)
Performance 
status of 0–1 
(%)
Median 
follow-up 
(survival)
Treatment on 
progression (control 
group only)
(Continued form previous page)
STAMPEDE 
(standard of 
care plus 
docetaxel 
with or 
without 
zoledronic 
acid)8
November, 
2005–March, 
2013
1185 ADT (plus radiotherapy 
for M0 patients) + 
docetaxel 
(75mg/m2/3wks/6cycles)
ADT (plus 
radiotherapy for M0 
patients) plus 
docetaxel (75 mg/m² 
every 3 weeks for six 
cycles) plus 
zoledronic acid (4 mg 
every 3–4 weeks for 
2 years)
M0 and M1 66
(40–84)
73% 99% 3 years, 
7 months
14% received further 
docetaxel (41% 
received life-extending 
treatments)
PRO512 June, 1994–July, 
1998
311 Local standard 
practice=radiotherapy or 
hormone therapy or both 
plus placebo
Local standard 
practice plus 
clodronate (520 mg 
four times daily)
M1 71
(47–88)
Unknown 94% 11 years, 
6 months
55 men received 
radiotherapy; 40 men 
“changed hormone 
therapy”
CALGB 
9020230
June, 2004–April, 
2012
645 ADT=bilateral 
orchidectomies, GnRH 
agonist or GnRH 
antagonist (and 
zoledronic acid placebo)
ADT plus zoledronic 
acid (4 mg 
intravenous every 
4 weeks)
M1 66·3
(60–73)
58% 97% 2 years 49% of the men in 
zoledronic acid group 
and 51% of men in the 
placebo group 
initiated open-label 
treatment with 
zoledronic acid
ADT=androgen deprivation therapy. LHRH=luteinising hormone-releasing hormone. PSA=prostate-speciﬁ c antigen.*This value is the mean (no SD was available) 
Table 1: Characteristics of studies included in the systematic review and meta-analysis
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each group and test for diﬀ erences between the groups 
using a χ² test for interaction and F ratio.23 If we found 
diﬀ erences in eﬀ ect by metastatic status, we planned 
to carry out the other trial group analyses separately 
within the M1 and M0 groups. We also planned to 
investigate whether there were interactions between 
any treatment eﬀ ect and any of the following 
covariates: age; performance status; TNM stage; 
Gleason score; whether newly diagnosed or not; 
previous androgen deprivation therapy; and (for M1 
disease only) the location and volume of all metastases 
and the volume of bone metastases. The interaction 
HR in each trial was calculated from the ratio of the 
estimated HRs for each subgroup (eg, the HR for 
previous androgen deprivation therapy divided by the 
HR for no previous androgen deprivation therapy); 
these HRs were then combined across trials using a 
ﬁ xed-eﬀ ect meta-analysis.24 We used Stata version 13 
for all analyses. 
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Our searches of bibliographic databases, trial registers, 
and conference proceedings identiﬁ ed 5141 articles and 
records (ﬁ gure 1). After removing obvious duplicates 
and records that were clearly irrelevant, 83 records of 
potentially eligible trials were thoroughly scrutinised. 
24 of these records were duplicates, and a further 
24 records were ineligible. In total, 35 trials were eligible; 
14 trials were eligible for inclusion in the docetaxel 
comparison, and 22 trials were eligible for the 
bisphosphonate comparison (table 1, table 2).25–47 One 
large multiarm trial (STAMPEDE),8 which incorporates 
multiple treatment comparisons in men with both M0 
and M1 disease, contributes to both the docetaxel and 
bisphosphonates meta-analyses.
Five trials compared standard of care with or without 
docetaxel in men with M1 disease. One trial 
(GOUP 01/04 [NCT00796458]), including 200 men, is 
still recruiting, and another trial,32 including 14 men, 
has yet to report suitable outcome data (table 2). In the 
three remaining trials,7,8,10 men aged 36–91 years 
(median 63–66 years) with a good performance 
status received androgen deprivation therapy-based 
treatments (standard of care) with or without docetaxel 
(table 1). Most men had presented with metastatic 
disease and were starting long-term androgen 
deprivation therapy for the ﬁ rst time. Docetaxel was 
Accrual dates Number of 
patients
Metastatic 
status
Primary outcome Secondary outcomes Reason not included
ADT vs ADT + docetaxel
ARTIC AOM-0310831 June, 2003–
November, 
2009
254 M0 PSA progression-free 
survival 
PSA response; duration of PSA response; time to 
clinical progression; overall survival; tolerability; 
quality of life
Reported results could not be used 
(safety 2010, progression-free 
survival* 2011, quality of life 2013)
GENTAX32 October, 2005–
December, 
2009
30 M0 and M1 Progression-free survival Overall survival; toxicity; quality of life Reported results could not be used 
(progression-free survival*)
SPCG-1333 May, 2007–
November, 
2004
378 M0 PSA progression PSA doubling time; quality of life; safety; metastasis-
free survival; overall survival
Reported results could not be used 
(safety)
TAX 350334 July, 2007–
September, 
2012
400 M0 Progression-free survival Overall survival; cancer-speciﬁ c survival; adverse events Reported results could not be used 
(safety)
CAN-NCIC-PR12 
(NCT00651326)
March, 2008–
January, 2011
48 M0 Disease-free survival Overall survival; time to biochemical disease 
progression; time to local or distant disease 
progression; time to next anti-cancer therapy; 
progression-free survival; degree of PSA suppression 
before radiotherapy; quality of life; adverse events
No results reported yet
QRT-SOGUG35 December, 
2008–
September, 
2012
134 M0 PSA relapse Unclear Reported results could not be used 
(toxicity)
05-043 
(NCT00116142)
June, 2005–
August, 2015
350 M0 Overall survival PSA doubling time; PSA failure; cancer-speciﬁ c survival No results reported yet
GOUP-01/04 
(NCT00796458)
April, 2005–
ongoing
200 M1 2-year progression-free 
survival
Overall survival; time to treatment failure; toxicity; PSA 
response rate; disease response rate; PSA 
normalisation; quality of life; control of bone pain; 
change in chromogranin A concentration; cost analysis
Ongoing
(Table 2 continues on next page)
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given at a standard dose of 75 mg/m² per cycle every 
3 weeks for six to nine cycles, and median follow-up 
ranged from 29 months to 82∙9 months (table 1). 
All trials were assessed as being at low risk of bias 
(table 3).
Survival data from these three trials7,8,10 were available 
for 2992 (93%) of 3206 men with M1 disease (table 1), 
and 1271 deaths had been recorded. Assuming a typical 
4-year survival with standard of care of 40%, the 
meta-analysis HR of 0·77 (95% CI 0·68–0·87; p<0·0001), 
Accrual dates Number of 
patients
Metastatic 
status
Primary outcome Secondary outcomes Reason not included
(Continued from previous page)
ADT vs ADT + bisphosphonates
Smith 200536 September, 
1999–March, 
2003
544 M0 Bone metastasis-free 
survival and overall 
survival
Time to ﬁ rst skeletal-related events; quality of life; pain Reported results could not be used 
(overall survival*, time to ﬁ rst bone 
metastasis)
Ryan 200737 January, 2000–
December, 
2002
42 M0 + M1 BMD Urinary NTX concentration and serum BAP 
concentration
Reported results could not be used 
(bone mineral density, urinary NTX, 
serum BAP)
Smith 200338 February, 
2000–
November, 
2000
106 M0 LS BMD Other bone mineral density Reported results could not be used 
(bone mineral density)
Israeli39 February, 
2003–May, 
2005
222 M0 LS BMD TH bone mineral density; serum NTX; serum BSAP Reported results could not be used 
(LS bone mineral density, TH bone 
mineral density, serum NTX)
Ryan 200640 April, 2003–
March, 2004
120 M0 FN/LS BMD Serum BSAP; urine NTX; TH BMD Reported results could not be used 
(bone mineral density, urinary NTX, 
serum BSAP)
Zenith 
(NCT00063609)
April, 2003–
April, 2005
200 M0 LS BMD TH BMD; markers of bone turnover No results reported yet
Rao41 June, 2003–
May, 2004
50 M0 BMD Urinary DPD Reported results could not be used 
(BMD)
HOG GU02-4142 December, 
2003–August, 
2005
63 M1 Skeletal-related events Time to castrate-resistant prostate cancer; markers of 
bone turnover
Reported results could not be used 
(skeletal-related events, castrate-
resistant prostate cancer, serological 
progression, prostate-speciﬁ c 
antigen nadir, adverse events, urine 
DPD, urine NTX, serum BAP)
Bhoopalam43 December, 
2003–May, 
2006
93 M0 LS bone mineral density NA Reported results could not be used 
(bone mineral density)
Casey44 Unclear 200 M0 LS bone mineral density FN/TH BMD; change in height; safety Reported results could not be used 
(bone mineral density)
Yedavelli45 Unclear 42 M0 Skeletal-related events Bone mineral density Reported results could not be used 
(bone mineral density)
Rodrigues46 Unclear 94 M0 Bone mineral density NA Reported results could not be used 
(bone mineral density)
CEGOG 
(NCT00294437)
December, 
2003–
November, 
2007
376 M0 Time to bone metastasis Pain; time to ﬁ rst bone pain; skeletal-related events; 
serum PSA; safety
No results reported yet
Ueno47 July, 2006–
June, 2011
60 M1 PSA progression-free 
survival
Skeletal-related events; bone pain; markers of bone 
turnover
Reported results could not be used 
(PSA and progression-free survival,* 
skeletal-related events, bone pain)
KYUHTRIGU0705 
(NCT00685646)
May, 2008–
December, 
2013
227 M1 Time to treatment failure Time to ﬁ rst skeletal-related event; overall survival; 
extent of disease; pain
No results reported yet
NU-02U1 
(NCT00058188)
March, 2003–
September, 
2015
70 M0 Bone mineral density LS bone mineral density No results reported yet
ADT=androgen deprivation therapy. NA=non-applicable. PSA=prostate-speciﬁ c antigen. NTX=N-terminal telopeptide. BAP=bone alkaline phosphatase. LS BMD=lumbar spine bone mineral density. 
FN/LS BMD=femoral neck/lumbar spine bone mineral density. TH BMD=total hip bone mineral density. BSAP=bone-speciﬁ c alkaline phosphatase. CRPC=castrate-resistant prostate cancer. DPD=deoxypridinoline. 
*Data reported not usable. 
Table 2: Characteristics of studies included in the systematic review that could not be included in the meta-analyses
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translates to a 9% (95% CI 5–14) absolute improvement 
with standard of care plus docetaxel relative to standard 
of care alone (ﬁ gure 2). We found no evidence of variation 
between the trial results. Statistical heterogeneity was 
very low throughout all analyses, so the estimates 
generated using a random-eﬀ ects model were consistent 
with those generated with the ﬁ xed-eﬀ ect model.
Failure-free survival was deﬁ ned similarly in all trials. 
However, in the STAMPEDE trial,8 only prostate cancer 
speciﬁ c deaths were included (rather than death by any 
cause), and in the CHAARTED trial7 the most similar 
reported outcome to our deﬁ nition of failure-free 
survival was time to hormone-refractory disease, which 
was deﬁ ned as the time from randomisation until 
clinical or serological progression. Results were 
available for the same 2992 men as for survival, and 
2204 events were recorded. Assuming a baseline 4-year 
failure-free survival of 20%, the meta-analysis HR of 
Adequate sequence 
generation
Allocation 
concealment
Masking Incomplete outcome data addressed Free of selective reporting
TAX 350127 Randomisation with 
stratiﬁ cation factors reported
Randomised NA All randomised patients included in the 
analyses
Yes, although survival not 
reported, data not mature
CHAARTED7 Randomisation with 
stratiﬁ cation factors reported
Centrally randomised NA All randomised patients included in the 
analyses
Yes, all outcomes of interest are 
reported
GETUG-1225,26 Randomisation with 
stratiﬁ cation factors reported
Centrally randomised NA All randomised patients included in the 
analyses
Yes, outcomes of interest are 
reported, although survival data 
reported are not yet mature
STAMPEDE8 Used a method of 
minimisation over a number of 
clinically important 
stratiﬁ cation factors with an 
additional random element
Central telephone 
randomisation
NA All randomised patients included in the 
analyses
Yes, outcomes of interest are 
reported
RTOG 052128 Randomisation with 
stratiﬁ cation factors reported
Centrally randomised NA 45 ineligible patients (3% of the total) were 
excluded from analyses; not clear if balanced 
by treatment group
Yes, outcomes of interest are 
reported
GETUG-159,10 Minimisation method with 
stratiﬁ cation factors reported
Centrally randomised NA All randomised patients included in the 
analyses
Yes, outcomes of interest are 
reported
CALGB 9020230 Randomised block design with 
stratiﬁ cation factors
Central online 
registration and 
randomisations
Double-blind or placebo-
controlled
All randomised patients are included in the 
eﬃ  cacy analyses
Reports survival, but not 
failure-free survival as deﬁ ned in 
the meta-analysis
RADAR21 Minimisation with a random 
element and stratiﬁ cation 
factors
Central trials oﬃ  ce 
computer based 
randomisation
Open label; the endpoints 
committee were unaware of 
patient identity or treatment 
assignment; treatment was 
not masked to the 
investigators, patients, or trial 
statistician
All randomised patients are included in the 
eﬃ  cacy analyses
Reports survival, but not 
failure-free survival as deﬁ ned in 
the meta-analysis
ZEUS29 Minimisation method 
described by Pocock53 with 
stratiﬁ cation factors
Central randomisation 
by fax
Open label 40 patients (3% of total randomised) 
excluded from analyses; seven patients were 
ineligible; 27 patients withdrew consent; six 
patients were lost to follow-up; exclusions 
are balanced by group
Reports survival, but not 
failure-free survival as deﬁ ned in 
the meta-analysis
PR0412 Minimisation method over ﬁ ve 
stratiﬁ cation factors
Central randomisation Double blind; placebo-
controlled; clinicians assessing 
cause of death were blinded to 
treatment allocation
In the primary analysis, no randomised 
patients were excluded from the analyses; in 
the analysis with long-term follow-up, 
37 patients were excluded as they had not 
been ﬂ agged with the NHS Information 
Centre
Reports survival, but not 
failure-free survival as deﬁ ned in 
the meta-analysis
PR0512 Minimisation method over four 
stratiﬁ cation factors
Central randomisation Double blind; placebo 
controlled
In the primary analysis, no randomised 
patients were excluded from the analyses; in 
the analysis with long-term follow-up, 
33 patients were excluded as they had not 
been ﬂ agged with the NHS Information 
Centre
Reports survival, but not 
failure-free survival as deﬁ ned in 
the meta-analysis
STAMPEDE8 Used a method of 
minimisation over a number of 
clinically important 
stratiﬁ cation factors with an 
additional random element
Central telephone 
randomisation
Open label All randomised patients included in the 
analyses
Yes, outcomes of interest are 
reported, including survival and 
failure-free survival
NA=non-applicable. NHS=National Health Service.
 Table 3: Assessment of risk of bias
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0·64 (95% CI 0·58–0·70; p<0·0001) translates to a 16% 
(95% CI 12–19) improvement, reducing failures from 
80% to 64% (ﬁ gure 2). Again, we found no evidence of 
variation between the trial results.
We identiﬁ ed 11 trials that compared standard of care 
with or without docetaxel for men with non-metastatic 
disease (M0). Two trials (CAN-NCIC-PR12 [NCT00651326] 
and 05-043 [NCT00116142]), including 398 men, have 
ﬁ nished accrual but have yet to report any results. 
Five trials,31–35 including 1196 men, have yet to report any 
survival outcomes (table 2). The four remaining trials,8,25,27,28 
all of which have reported survival or failure-free survival, 
or both, were included in the meta-analysis. Men of 
median age 62–66 years (ranges not reported for all trials) 
with non-metastatic disease and good performance status 
were randomly assigned to receive standard of care with 
or without docetaxel (table 1). Docetaxel was given at a 
standard dose of 75 mg/m² per cycle every 3 weeks for 
six cycles, except in one trial,25 which used docetaxel 
70 mg/m² plus estramustine 10 mg/kg on days 1–5 of 
each cycle. Median follow-up across the trials ranged from 
39 months to 90 months (table 1). All trials were assessed 
as being at low risk of bias (table 3).
Survival data were available for 2121 (53%) of 3978 men 
from three of the four trials,8,25,28 and 340 deaths have been 
recorded. The meta-analysis HR of 0∙87 (95% CI 
0·69–1·09; p=0·218) translates to a potential absolute 
improvement of 2% (95% CI –2 to 7), assuming a typical 
baseline 4-year survival of 80% (ﬁ gure 2); however, the 
conﬁ dence intervals are wide, and the result is not 
statistically signiﬁ cant. We found no evidence of variation 
between the trial results.
Failure-free survival was deﬁ ned consistently in all four 
trials,8,25,27,28 but in the STAMPEDE trial,8 only prostate 
cancer-speciﬁ c deaths were included (rather than death 
by any cause), and the GETUG-12 trial26 included 
time-to-salvage treatment. Results were available for 
2348 (59%) of the 3798 men included in all four trials, and 
851 events have been recorded. The meta-analysis HR of 
0·70 (95% CI 0·61–0·81; p<0·0001) translates to an 
absolute improvement of 8% (95% CI 5–10), reducing 
4-year failure rates from 30% to 22%, assuming a baseline 
4-year failure-free survival of 70% (ﬁ gure 2). Again, no 
evidence exists of variation between the trial results.
We identiﬁ ed seven trials that compared standard of 
care with or without bisphosphonates in men with M1 
disease. The results of one trial (KYUH-TRIGU0705 
[NCT00685646]), including 227 men, have yet to be 
reported, and in three other trials,37,42,47 including 142 men, 
skeletal-related events, changes in bone mineral density, 
or both were the primary outcomes, and survival was not 
reported (table 2). In the three remaining trials,8,12,30 men 
of median age 66–71 years (range 40–88) with good 
performance status were randomly assigned to receive 
standard of care with or without either zoledronic acid8,30 
or sodium clodronate12 (table 1). Zoledronic acid was 
given at a dose of 4 mg every 3–4 weeks for either 2 years 
or until disease progression. Sodium clodronate was 
given orally at 2080 mg daily for up to 3 years (table 1). 
Median follow-up in the trials ranged from 24·4 months 
to 138 months (table 1). All trials were assessed as being at 
low risk of bias (table 3).
Survival results were available for 2740 (88%) of 3109 men 
from three trials, and 1365 deaths have been recorded. 
The meta-analysis HR of 0·88 (95% CI 0·79–0·98; 
Figure 2: Eﬀ ect of addition of docetaxel to standard of care on survival and failure-free survival
(A) Eﬀ ect of the addition of docetaxel on survival in men with M1 disease. (B) Eﬀ ect of the addition of docetaxel on 
failure-free survival in men with M1 disease. (C) Eﬀ ect of the addition of docetaxel on survival in men with M0 
disease. (D) Eﬀ ect of the addition of docetaxel on failure-free survival in men with M0 disease. NA=event numbers 
by group not available. SOC=standard of care.
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p=0·025) translates to a 5% (95% CI 1–8) absolute 
improvement with standard of care plus bisphosphonates, 
assuming a baseline 4-year survival of 40% in men with 
M1 disease (ﬁ gure 3). We found no evidence of variation 
between the trial results. However, when the analysis was 
restricted to the two trials (1107 deaths among 2462 men) 
that compared standard of care with and without 
zoledronic acid, we found no evidence of a beneﬁ t of 
standard of care plus zoledronic acid (HR 0·94 
[95% CI 0·83–1·07]; p=0·323), with a potential absolute 
improvement in survival of 2% (95% CI –3 to 7; ﬁ gure 3), 
although these diﬀ erences were not statistically signiﬁ cant. 
In the one trial of sodium clodronate,12 a clear treatment 
beneﬁ t was reported (HR 0·77 [95% CI 0·60–0·98], 
p=0·032).
Failure-free survival was only reported in one trial, 
with other trials reporting a variety of intermediate 
outcomes (eg, bone metastases-free survival, time to ﬁ rst 
skeletal-related event), such that no formal meta-analysis 
was possible.
We identiﬁ ed 17 trials that compared standard of care 
with or without bisphosphonates for men with 
M0 disease. The results of three trials (CECOG 
[NCT00181584], ZENITH [NCT00063609], and NU-02U1 
[NCT00058188]), including 646 men, are unpublished, 
and ten other trials,36–41,43–46 including 1494 men, have 
reported results for outcomes other than survival 
(table 2). In the four remaining trials8,12,21,29 included in 
the meta-analysis, men aged 40–87 years (median 
66–70 years) with good performance status were 
randomly assigned to receive standard of care with or 
without either zoledronic acid8,21,29 or sodium clodronate12 
(table 1). In two of the trials,21,29 zoledronic acid was given 
at a dose of 4 mg every 3 months for either 18 months or 
4 years, whereas in the third trial,8 zoledronic acid 4 mg 
was given every 3 weeks for 2 years. Sodium clodronate 
was given orally at 2080 mg every day for up to 5 years. 
Median follow-up across the trials ranged from 
42 to 144 months (table 1). All trials were assessed as 
being at low risk of bias (table 3).
Survival results were available for 4079 (66%) of 
6220 men from four trials, and 918 deaths have been 
recorded. We found no evidence that bisphosphonates 
improve survival when added to standard of care (HR 1·03 
[95% CI 0·89–1·18]; p=0·724). Assuming a baseline 4-year 
survival of 80%, this HR translates to a potential absolute 
detriment in survival of 1% (95% CI –3 to 2; ﬁ gure 3), 
although this is not statistically signiﬁ cant, and we found 
no evidence of variation between the trial results. Results 
were similar when the analysis was restricted to trials that 
tested standard of care with or without zoledronic acid 
(three trials, 637 deaths, 3608 men; HR 0·98 [0·82–1·16]; 
p=0·782), suggesting no potential absolute improvement 
in survival (0%, [95% CI –3 to 3]; ﬁ gure 3), again with no 
evidence of variation between the trial results. Failure-free 
survival was only reported in one trial so no formal 
meta-analysis was done.
For both the docetaxel and bisphosphonate com-
parisons, far fewer results were available for the M0 
disease setting than for the M1 setting, which is why the 
meta-analyses for the M1 and M0 settings are presented 
separately. Moreover, within these meta-analyses, not 
enough trials have assessed whether any eﬀ ect varied by 
other trial characteristics (eg, use of radiotherapy plus 
androgen deprivation therapy). Also, results by patient 
Figure 3: Eﬀ ect of addition of bisphosphonates to standard of care on survival 
(A) Eﬀ ect of the addition of bisphosphonates on survival in men with M1 disease. (B) Eﬀ ect of the addition of 
zoledronic acid on survival in men with M1 disease. (C) Eﬀ ect of the addition of bisphosphonates on survival in 
men with M0 disease. (D) Eﬀ ect of the addition of zoledronic acid on survival in men with M0 disease. NA=event 
numbers by group not available. SOC=standard of care.
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subgroup were either too sparse, or the deﬁ nitions too 
inconsistent, to allow for meaningful analyses from the 
available reported data.
Discussion
This meta-analysis provides substantial and reliable 
evidence that adding docetaxel to standard of care 
improves the survival of men with M1 disease, with an 
absolute improvement of around 9% at 4 years. For men 
with M0 disease, evidence to date supports an 8% 
reduction in absolute failure rates at 4 years with 
docetaxel, but the evidence is insuﬃ  cient to reliably 
assess the eﬀ ects on survival. Although evidence 
suggests improved survival with the addition of 
bisphosphonates to standard of care for men with M1 
prostate cancer, this eﬀ ect appeared to be largely driven 
by one trial of the drug sodium clodronate, and our 
results suggest that any potential beneﬁ t of zoledronic 
acid is small. We found no evidence that bisphosphonates 
improve survival in men with M0 disease.
The results are reliable and robust for men with M1 
hormone-sensitive prostate cancer treated with 
docetaxel because, although based on three trials only, 
these results are derived from 93% of all men who 
were randomly assigned to treatment groups and 1271 
deaths. Although additional results might become 
available in this setting, from both the GOUP 01/04 
and the GENTAX32 trials, these results are unlikely to 
materially aﬀ ect our ﬁ ndings. Importantly, however, in 
three of the included trials7,8,10 most of the men who 
were randomly assigned to treatment groups were 
newly diagnosed with metastatic disease. A few men 
had progressed after previous diagnoses of localised 
disease, and results for this speciﬁ c subgroup were not 
reported. While we see no reason for why the observed 
beneﬁ t of docetaxel should not be generalisable, the 
only way to appropriately assess this, or any other 
remaining questions, is through the collection and 
re-analysis of individual participant data. Across the 
three trials, the number of reported grade 3–4 toxic 
eﬀ ects increased with docetaxel, most commonly 
neutropenia. Overall, 16 deaths were attributed to 
docetaxel. Nevertheless, docetaxel combined with 
androgen deprivation therapy should be considered a 
new standard of care for men with metastatic disease 
starting on long-term androgen deprivation therapy 
for the ﬁ rst time who are ﬁ t to receive chemotherapy 
and willing to accept these risks. Future trials in this 
setting should also consider this as an appropriate 
control group.48
In men with non-metastatic disease, we found 
evidence that docetaxel improves failure-free survival; 
however, this conclusion is based on data from four 
trials including just over half of all men who were 
randomly assigned to treatment groups. Nevertheless, as 
the estimate of eﬀ ect (HR 0·70) is in keeping with that 
for men with metastatic disease (HR 0·64) and the 
conﬁ dence interval is narrow, this ﬁ nding provides a 
clear and early signal of potential beneﬁ t. For overall 
survival, however, the available data are less mature, 
such that the estimate of eﬀ ect is based on half of all 
men who were randomly assigned to treatment groups 
and 340 deaths, and the conﬁ dence interval is wide. This 
meta-analysis will be important to update, to include 
mature results of unreported trials and long-term follow-
up of those already reported, to reliably assess any eﬀ ect 
of docetaxel on survival. We will need to collaborate with 
trial investigators to determine when these data are 
likely to emerge so that we can predict when a 
meta-analysis that includes a much larger proportion of 
the men randomised in this setting and provides 
suﬃ  cient power to detect moderate survival beneﬁ ts will 
be feasible. Importantly, as a notable proportion of men 
will die from causes other than prostate cancer, any 
treatment eﬀ ect on survival is likely to be diluted. Thus, 
we will also need to examine the eﬀ ects of docetaxel on 
prostate cancer-speciﬁ c survival, which will only be 
possible through our planned international individual 
participant data meta-analysis.
Despite the beneﬁ ts of bisphosphonates with respect 
to skeletal-related events and bone pain,49,50 the eﬀ ect of 
bisphosphonates on survival in men with hormone-
sensitive prostate cancer is less clear. In men with M1 
disease, although based only on three trials, these 
results represent 87% of men who were randomly 
assigned to treatment groups and suggest a small 
potential survival beneﬁ t. However, this result is driven 
largely by the outcome of the PR05 trial,12 which showed 
a beneﬁ t of sodium clodronate. In view of the 
diﬀ erences in mechanisms of action between 
clodronate and zoledronic acid, we planned analyses 
that considered trials of the two treatments separately. 
Moreover, as sodium clodronate is not commonly used 
in practice, our focus is on the ﬁ ndings relating to 
zoledronic acid. The four additional trials, which have 
yet to report survival, randomly assigned fewer than 
400 patients in total and so will probably not alter the 
results. Moreover, the results to date suggest that any 
absolute beneﬁ t from zoledronic acid is likely to be 
small at best. In the non-metastatic setting, although 
based on only four of 17 trials, the analysis includes 
around 65% of randomly assigned men, and we found 
no evidence of a beneﬁ t of bisphosphonates on survival. 
Data from other identiﬁ ed trials might provide enough 
power to detect a small beneﬁ t, but our results at 
present suggest that even a small beneﬁ t of zoledronic 
acid is unlikely.
In both the metastatic and non-metastatic disease 
settings, we are aware of a number of limitations of a 
meta-analysis based on the reported trials of 
bisphosphonates, not least that many of the trials 
identiﬁ ed in the systematic review have not reported 
survival and so could not contribute to the meta-analysis. 
Crossover policies and actual treatment on progression 
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varies between the included trials. For example, in the 
STAMPEDE trial,8 treatment was stopped at the time of 
progression, whereas in the CALGB 90202 trial,30 
patients crossed over to receive zoledronic acid when 
evidence of biochemical failure was found. The potential 
eﬀ ect of treatment crossover on overall survival is 
unclear. Therefore, an analysis of failure-free survival 
remains important; however, variations in deﬁ nition 
meant that this was not possible from the reported data. 
The collection of individual participant data, or 
alternatively, provision or consistent reporting of 
results would enable us to better ascertain the role for 
bisphosphonates on other outcomes. The ongoing 
ICECaP initiative51 should help deﬁ ne the most 
appropriate intermediate outcomes in men with 
hormone-sensitive prostate cancer.
Rigorous systematic review methods helped us 
identify all relevant trials in the two treatment 
comparisons, irrespective of whether they were 
completed or reported. This approach allowed us to 
decide prospectively when we would be likely to have 
suﬃ  cient data and power to detect meaningful eﬀ ects of 
docetaxel or bisphosphonates in combination with 
standard of care, at least in the M1 disease setting. 
Despite knowing that there would be fewer data and 
less power to assess the eﬀ ects of both treatments in the 
non-metastatic disease setting than in the metastatic 
disease setting, we have been able to establish early 
signals of both beneﬁ t (docetaxel) and no beneﬁ t 
(bisphosphonates), consistency of results with those in 
metastatic disease, and whether new data are likely to 
change the results. By using an approach that is 
responsive to the emerging trial results and adaptive to 
potential future data, we have been able to achieve 
robust answers to speciﬁ c therapeutic questions quickly 
and determine which meta-analyses will need updating 
in the future and which will require individual patient 
data for more reliable and detailed results.
In summary, for men with metastatic prostate cancer 
starting therapy for the ﬁ rst time, we found strong 
evidence to support the addition of docetaxel to 
androgen deprivation therapy as the new standard of 
care, and this combination should be oﬀ ered to men 
who are ﬁ t to receive chemotherapy. More reliable 
evidence of the eﬀ ect of docetaxel on overall survival 
and prostate cancer-speciﬁ c survival is still needed in 
the M0 disease setting and will be achieved through our 
planned collaborative international meta-analysis of 
individual participant data. This project will also allow 
us to investigate whether eﬀ ects vary by patient or 
tumour characteristics. We found no evidence that 
zoledronic acid improves survival in men with either 
metastatic or non-metastatic hormone-sensitive disease. 
Although additional trials are yet to be reported, the 
suggestion from our analyses is that any likely beneﬁ t of 
zoledronic acid will probably be small and not clinically 
meaningful.
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